Comparative Pharmacology
Head-to-head clinical analysis: LOCHOLEST versus WELCHOL.
Head-to-head clinical analysis: LOCHOLEST versus WELCHOL.
LOCHOLEST vs WELCHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Locholest is a bile acid sequestrant that binds bile acids in the intestine, preventing their reabsorption and promoting fecal excretion. This leads to increased hepatic conversion of cholesterol to bile acids, reducing serum LDL cholesterol.
Welchol (colesevelam) is a bile acid sequestrant. It binds to bile acids in the intestine, forming an insoluble complex that is excreted in the feces. This disrupts the enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, resulting in decreased serum low-density lipoprotein cholesterol (LDL-C). Additionally, colesevelam may improve glycemic control in type 2 diabetes by binding to bile acids, which alters farnesoid X receptor (FXR) and TGR5 signaling, leading to increased glucagon-like peptide-1 (GLP-1) secretion and improved insulin sensitivity.
Initial dose: 10-20 mg orally once daily, taken in the evening. Titrate as tolerated every 4 weeks to a maximum of 80 mg once daily.
Adults: 625 mg to 1.875 g orally twice daily, with meals. Maximum 4.375 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 19 hours (range 14-47 hours) for patients with normal renal function; accumulation occurs with once-daily dosing.
Not applicable; colesevelam acts locally in the gastrointestinal tract and is not absorbed systemically. Terminal half-life is not measurable in conventional pharmacokinetic sense due to negligible systemic absorption.
Primarily fecal (biliary) as unchanged drug; renal excretion <5%.
Primarily fecal as unchanged drug (approximately 85%), with less than 0.5% renal excretion of absorbed drug; no biliary excretion due to non-absorbed nature.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant